Background: Many features of anticancer drugs, including cytotoxicity and/or cytokine induction, are studied using cell lines orhuman blood leukocytes. However, in a disease such as multiple myeloma, most cancerous cells are resided within bone marrowmononuclear cells. In the present study, we investigated the effect of pomalidomide on apoptosis and IL-2 production of bonemarrow mononuclear cel...

objective(s): the aim of this study was to investigate the methylation status and mrna expression levels of p15, death-associated protein kinase (dapk), and suppressor of cytokine signaling-1 (socs1) genes in multiple myeloma (mm). materials and methods: the bone marrow samples of 54 mm patients were collected and the methylation status of the p15, dapk, and socs1 gene promoter regions was dete...

extramedullary plasmacytomas are plasma cell tumors that arise outside the bone marrow. they are most often located in the head and neck. extramedullary plasmacytomas account for approximately 3 percent of plasma cell malignancies. the diagnosis of an extramedullary plasmacytoma depends upon the demonstration of a monoclonal plasma cell tumor at an extramedullary site with no evidence of multip...

objective: multiple myeloma (mm) is a plasma cell malignancy where plasma cells are increased in the bone marrow (bm) and usually do not enter peripheral blood, but produce harmful factors creating problems in these patients (e.g. malignant plasma cells over activate osteoclasts and inhibit osteoblasts with factors like rankl and dkk). these factors are a main cause of bone lesion in mm patient...

Background: CD93 has originally been known as a C1q receptor, and many studies have demonstrated that CD93 is expressed on hematopoietic stem cells, B cell progenitors, myeloid and monocytic cells. Moreover, CD93 is shown to be expressed on long-lived plasma cells, and CD93 deficient-mice display an impairment in plasma cell development. Objective: To investiga...

Background: Multiple myeloma (MM) is a plasma cell disorder characterized by presence of monoclonal protein in serum or urine or both, increased bone marrow plasma cells, osteolytic lesion, hypercalcemia, and anemia. Several combination regimens are commonly recommended for treatment of multiple myeloma. The present study aimed at determining the characteristics and outcomes of patients with mu...

Introduction: Multiple myeloma is a heterogeneous disease with different survival times among patients. Accurate prediction of prognosis in multiple myeloma is essential, as patients with a shorter survival time may require early bone marrow transplantation (BMT) and more advanced chemotherapy as a part of their first-line treatment. In the present study, a parameter, depicted by ga...